GlassScriptPhysician profile
Salah Qureshi
NPI 1487833042
$806.26
in general payments reported to CMS, 2019-2025
17 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $126 · 2021: $68.18 · 2022: $12.13 · 2023: $60.63 · 2024: $205 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $463.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $174.83 | 2019-2024 | Spravato |
| Corium, LLC | $114.39 | 2024-2025 | Azstarys |
| Abbvie INC. | $95.49 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.04 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $58.79 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $48.38 | 2023-2024 | Fanapt |
| Alkermes, INC. | $41.45 | 2019-2024 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $40.09 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.93 | 2024 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $26.56 | 2019 | |
| Exact Sciences Corporation | $24.46 | 2025 | The Cologuard Plus Collection Kit |
| Luye Pharma (USA) LTD. | $20.81 | 2025 | Erzofri Extended-Release |
| Neurocrine Biosciences, INC. | $19.00 | 2019 | |
| Tris Pharma INC | $17.58 | 2025 | Dyanavel Xr |
| Almatica Pharma LLC | $16.06 | 2025 | Loreev Xr |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $15.40 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salah Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.